<DOC>
	<DOC>NCT01002950</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the investigational drug ACU-4429 in subjects with geographic atrophy.</brief_summary>
	<brief_title>Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<criteria>Have a clinical diagnosis of geographic atrophy, as defined in the protocol Currently receiving or has received a medication prohibited by the protocol</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>